Gabaergic receptor subtype selective ligands and their uses

Cook, J. M., Clayton, T. S., Jain, H. D., Johnson, Y. T., Yang, J., Rallipalli, S. K., Wang, Z., Namjoshi, O. A., & Poe, M. M. (2015). Gabaergic receptor subtype selective ligands and their uses. (U.S. Patent No. US20150258128A1). https://patents.google.com/patent/US20150258128A1/en?oq=Cook%2c+J.+M.%2c+Clayton%2c+T.+S.%2c+Jain%2c+H.+D.%2c+Rallapalli%2c+S.%2c+Johnson%2c+Y.-T.%2c+Poe%2c+M.%2c+Namjoshi%2c+O.+A.%2c+%26+Wang%2c+Z.-J.+(2015).+Gabaergic+receptor+subtype+selective+ligands+and+their+uses.+U.S.+Patent+number+US2015%2f0258128A1.+Filed+March+03%2c+2015;+published+September+17%2c+2015

Abstract

Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Use of a web-based portal to return normal individual research results in Early Check
Article

The importance of quality data to track global progress in addressing stillbirths and neonatal mortality
Article

Pre-natal exposure to NO2 and PM2.5 and newborn lung function